Study
Semaglutide and the Pathogenesis of Progressive Neurodegenerative Disease: The Central Role of Mitochondria
Semaglutide may protect brain mitochondria in Parkinson’s.
Summary
In plain language
Details
Use the full description to understand the study design, methods, and the limits of the findings.
This research investigates the potential neuroprotective effects of semaglutide, a GLP-1 agonist, on progressive neurodegenerative diseases. The study examines how this diabetes medication may influence neuroinflammation, protein aggregation, and cognitive decline.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
Semaglutide and the Pathogenesis of Progressive Neurodegenerative Disease: The Central Role of Mitochondria
Published October 2025
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored March 30, 2026 using rubric v8_2026-03-10.
Assessment
The study is a consensus document discussing the potential neuroprotective effects of semaglutide. While it is published in a reputable journal, the methodology lacks detail, and the panel's diversity is unclear. The study is relevant to conditions affecting seniors but does not focus exclusively on this age group.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Consensus methodology | 6.7/10 | |
| Panel composition & bias | 5.0/10 | |
| Statistical methods | Not applicable to this type of study | |
| Transparency & process | 5.0/10 | |
| Conflicts & funding | 5.0/10 | |
| Endorsement & adoption | 0.0/10 | |
| Relevance to chosen population | 5.0/10 | |
| Publishing body quality | 10.0/10 | |
Additional Notes
The study provides a theoretical framework for semaglutide's effects on neurodegenerative diseases but lacks empirical data.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.